Journal
ANTIVIRAL RESEARCH
Volume 105, Issue -, Pages 100-111Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2014.02.013
Keywords
Hepatitis C; Neutralization; Epitope; Transmission; HCV E2 core
Categories
Funding
- Medical Research Council [G0801169]
- European Union [Health-F4-2012-305600]
- NIHR NDDC BRU
- Medical Research Council [G0400802, G0801169, MC_G0900866, G1100247] Funding Source: researchfish
- MRC [G0801169, G1100247, MC_G0900866, G0400802] Funding Source: UKRI
Ask authors/readers for more resources
Hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma worldwide. HCV establishes a chronic infection in the majority of cases. However, some individuals clear the virus, demonstrating a protective role for the host immune response. Although new all-oral drug combinations may soon replace traditional ribavirin-interferon therapy, the emerging drug cocktails will be expensive and associated with side-effects and resistance, making a global vaccine an urgent priority. T cells are widely accepted to play an essential role in clearing acute HCV infection, whereas the role antibodies play in resolution and disease pathogenesis is less well understood. Recent studies have provided an insight into viral neutralizing determinants and the protective role of antibodies during infection. This review provides a historical perspective of the role neutralizing antibodies play in HCV infection and discusses the therapeutic benefits of antibody-based therapies. This article forms part of a symposium in Antiviral Research on Hepatitis C: next steps toward global eradication. (c) 2014 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available